Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VYNE Therapeutics ( (VYNE) ) has shared an update.
On September 11, 2025, VYNE Therapeutics received a notification from Nasdaq indicating non-compliance with the minimum closing bid price requirement of $1.00 per share, as their stock price was below this threshold for 30 consecutive business days. The company has until March 10, 2026, to regain compliance, during which its stock will continue to trade on the Nasdaq Capital Market. VYNE is exploring options to meet the requirement, including a potential reverse stock split, but there is no assurance of compliance. Failure to comply by the deadline could result in delisting, though a second compliance period may be available if certain conditions are met.
The most recent analyst rating on (VYNE) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Underperform.
VYNE Therapeutics faces significant challenges, with financial instability, negative technical indicators, and a recent setback in its clinical trials. These factors contribute to a low stock score, underscoring the risks associated with investing in VYNE at this time.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapies for dermatology and other diseases.
Average Trading Volume: 2,290,636
Technical Sentiment Signal: Sell
Current Market Cap: $8.04M
For detailed information about VYNE stock, go to TipRanks’ Stock Analysis page.